Research on Amyotrophic Lateral Sclerosis and related conditions
Clinical Research in Amyotrophic Lateral Sclerosis
This study is trying to understand how ALS relates to other nerve diseases and to find new ways to track its progress by looking at people with ALS, those at risk, and healthy individuals.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Miami Academic / other |
| Locations | 1 site (Miami, Florida) |
| Trial ID | NCT00136500 on ClinicalTrials.gov |
What this trial studies
This observational study, known as CRiALS, aims to recruit participants to explore the complex relationship between Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative disorders. The research focuses on developing biomarkers for ALS and understanding the natural history of the disease from pre-symptomatic stages to late-stage progression. Participants include individuals with ALS, those at genetic risk, and healthy controls, allowing for a comprehensive evaluation of the disease's impact. The study is conducted by the ALS Research Collaboration at the University of Miami.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with ALS, those at genetic risk for ALS, and healthy controls.
Not a fit: Patients with other neurological or medical conditions that could confound the study results may not benefit from participation.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and early detection of ALS, potentially enhancing patient outcomes.
How similar studies have performed: Other studies have shown promise in understanding ALS through similar observational approaches, indicating potential for meaningful insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. At least 18 years of age. 2. Member of at least one of the following categories: 1. Individuals affected with ALS or a related neurodegenerative disease (sporadic or familial) 2. Unaffected individuals from fALS pedigrees, including pre-symptomatic individuals at genetic risk for ALS or individuals from pedigrees of ALS related diseases. 3. Healthy controls 3. Able and willing to comply with relevant procedures. Exclusion Criteria: 1\. Subject has a condition or is in a situation which, in the PI's opinion, could confound the study finding or may interfere significantly with the individual's participation and compliance with the study protocol -- including but not limited to neurological, psychological and/or medical conditions (e.g., multiple sclerosis, neuropathy, myelopathy).
Where this trial is running
Miami, Florida
- University of Miami — Miami, Florida, United States (Recruiting)
Study contacts
- Principal investigator: Michael Benatar, MD, PhD. — University of Miami
- Study coordinator: Anne-Laure Grignon, MD
- Email: fals@med.miami.edu
- Phone: 888-413-9315
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.